Letter

Over the counter medicines

Don’t include trimethoprim

BMJ 2008; 336 doi: 10.1136/bmj.39542.480324.3A (Published 10 April 2008)
Cite this as: BMJ 2008;336:787.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Robin A Howe, head, Welsh Antimicrobial Resistance Programme, National Public Health Service for Wales
  1. 1Cardiff Microbiology (Velindre NHS Trust), University Hospital of Wales, Cardiff CF14 4XW
  1. robin.howe{at}nphs.wales.nhs.uk

    The Medicines and Healthcare Products Regulatory Agency (MHRA) moves to recommend, for the first time, that a systemic antibiotic (trimethoprim) should have its licence reclassified from prescription only medicine (POM) to pharmacy (P) availability.1 For systemic antibiotics particular concerns exist that do not apply to other medicines.

    The use of antibiotics may have an adverse effect not only on the specific patient but also on the public health of the community. Quantifying the relation between antibiotic exposure and resistance …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular